{"id":"topotecan-chemotherapy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL84","moleculeType":"Small molecule","molecularWeight":"421.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting topoisomerase I, topotecan prevents cancer cells from replicating and ultimately leads to cell death. This mechanism is particularly effective in rapidly dividing cancer cells. Topotecan's ability to target topoisomerase I also makes it more effective in certain types of cancer, such as ovarian and small cell lung cancer.","oneSentence":"Topotecan is a topoisomerase I inhibitor that works by interfering with the enzyme topoisomerase I, which is involved in DNA replication and repair.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:29.847Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic ovarian cancer"},{"name":"Small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT04994977","phase":"PHASE1","title":"Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2023-05-04","conditions":"Atypical Choroid Plexus Papilloma, Choroid Plexus Carcinoma","enrollment":1},{"nctId":"NCT07214779","phase":"PHASE3","title":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-12-09","conditions":"Ovarian Cancer","enrollment":466},{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT07286266","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-24","conditions":"Ovarian Neoplasms","enrollment":450},{"nctId":"NCT05990738","phase":"PHASE1","title":"DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-02-14","conditions":"Small Cell Lung Carcinoma (SCLC)","enrollment":69},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT06449209","phase":"PHASE2","title":"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2024-08-05","conditions":"Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer","enrollment":110},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT06647953","phase":"PHASE3","title":"Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-03-21","conditions":"Pleuropulmonary Blastoma","enrollment":110},{"nctId":"NCT04697628","phase":"PHASE3","title":"Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer","status":"COMPLETED","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2021-02-22","conditions":"Cervical Cancer","enrollment":502},{"nctId":"NCT04322318","phase":"PHASE2","title":"A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-10-19","conditions":"Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor","enrollment":256},{"nctId":"NCT07418749","phase":"PHASE3","title":"A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"Recurrent Cervical Cancer, Metastatic Cervical Cancer","enrollment":398},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT06937905","phase":"PHASE3","title":"Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2026-02-06","conditions":"Neuroendocrine Carcinoma","enrollment":129},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT05421897","phase":"PHASE1","title":"Rapid Administration Pilot for Infusing Dinutuximab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Los Angeles","startDate":"2022-11-29","conditions":"Neuroblastoma","enrollment":11},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT01231906","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2010-11-24","conditions":"Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues","enrollment":642},{"nctId":"NCT07218809","phase":"PHASE3","title":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-29","conditions":"Epithelial Ovarian Cancer","enrollment":1100},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT06861244","phase":"PHASE2","title":"Embryonal Tumor With Multilayered Rosettes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-06","conditions":"Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos","enrollment":70},{"nctId":"NCT05740566","phase":"PHASE3","title":"Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2023-05-31","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":509},{"nctId":"NCT07189455","phase":"PHASE3","title":"Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2025-12-12","conditions":"Small-cell Lung Cancer","enrollment":420},{"nctId":"NCT03651206","phase":"PHASE2, PHASE3","title":"Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib","status":"RECRUITING","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2020-07-15","conditions":"Ovarian Carcinosarcoma, Endometrial Carcinosarcoma","enrollment":138},{"nctId":"NCT06855069","phase":"PHASE3","title":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-03-13","conditions":"Ovarian Cancer","enrollment":468},{"nctId":"NCT02364713","phase":"PHASE2","title":"MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-03-13","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":17},{"nctId":"NCT05521984","phase":"PHASE1","title":"Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-04-03","conditions":"Pediatric Brain Tumor, Pediatric Solid Tumor","enrollment":20},{"nctId":"NCT04681417","phase":"PHASE2, PHASE3","title":"Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2021-03-25","conditions":"Retinoblastoma","enrollment":225},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153},{"nctId":"NCT07230626","phase":"PHASE3","title":"SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-11-20","conditions":"Cervical Cancer","enrollment":412},{"nctId":"NCT05613088","phase":"PHASE2","title":"A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-02-01","conditions":"Neoplasms, Ovarian","enrollment":106},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT02514447","phase":"PHASE1, PHASE2","title":"Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy","status":"COMPLETED","sponsor":"G1 Therapeutics, Inc.","startDate":"2015-10-05","conditions":"Small Cell Lung Cancer","enrollment":123},{"nctId":"NCT05870748","phase":"PHASE2, PHASE3","title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","status":"TERMINATED","sponsor":"Sutro Biopharma, Inc.","startDate":"2023-07-12","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":600},{"nctId":"NCT01012817","phase":"PHASE1, PHASE2","title":"Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-11-03","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma","enrollment":88},{"nctId":"NCT03107988","phase":"PHASE1","title":"NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2017-09-05","conditions":"Neuroblastoma","enrollment":65},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT04908787","phase":"PHASE3","title":"A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-06-11","conditions":"Ovarian Cancer","enrollment":421},{"nctId":"NCT07145333","phase":"PHASE2, PHASE3","title":"Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2025-08-12","conditions":"SCLC","enrollment":600},{"nctId":"NCT05874401","phase":"PHASE4","title":"Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan","status":"RECRUITING","sponsor":"Pharmacosmos A/S","startDate":"2023-10-18","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":302},{"nctId":"NCT00186888","phase":"PHASE3","title":"Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2005-04-07","conditions":"Retinoblastoma, Retinal Neoplasm","enrollment":107},{"nctId":"NCT03165292","phase":"PHASE2","title":"Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-10-01","conditions":"Very High Risk Neuroblastoma","enrollment":34},{"nctId":"NCT05092360","phase":"PHASE3","title":"Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)","status":"TERMINATED","sponsor":"Mural Oncology, Inc","startDate":"2022-01-10","conditions":"Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":456},{"nctId":"NCT04209855","phase":"PHASE3","title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-12-31","conditions":"Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":453},{"nctId":"NCT07141771","phase":"PHASE1, PHASE2","title":"An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-12-31","conditions":"SCLC, Extensive Stage","enrollment":100},{"nctId":"NCT06994195","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-08-04","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":384},{"nctId":"NCT07106528","phase":"PHASE2, PHASE3","title":"Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-08","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Small Cell Lung Cancer ( SCLC )","enrollment":128},{"nctId":"NCT04947501","phase":"EARLY_PHASE1","title":"A Study of N9 Chemotherapy in Children With Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-06-22","conditions":"Neuroblastoma, Pediatric Cancer","enrollment":26},{"nctId":"NCT07076095","phase":"PHASE2","title":"A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","startDate":"2025-08-01","conditions":"Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT00308165","phase":"PHASE1","title":"Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors","status":"COMPLETED","sponsor":"Jeffrey N. Bruce","startDate":"2004-03","conditions":"Brain Neoplasms, Primary Malignant","enrollment":16},{"nctId":"NCT06954246","phase":"PHASE3","title":"A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-06-04","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":450},{"nctId":"NCT02419495","phase":"PHASE1","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-26","conditions":"Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":221},{"nctId":"NCT05101551","phase":"PHASE1","title":"Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy","status":"RECRUITING","sponsor":"Norman J. Lacayo","startDate":"2023-02-23","conditions":"Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT06990503","phase":"PHASE3","title":"SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-01","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT06500026","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-08-07","conditions":"Small Cell Lung Cancer","enrollment":714},{"nctId":"NCT06933394","phase":"PHASE2","title":"Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-05-01","conditions":"Neuroblastoma","enrollment":92},{"nctId":"NCT03475121","phase":"PHASE3","title":"Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma","status":"COMPLETED","sponsor":"Hospital JP Garrahan","startDate":"2018-01-01","conditions":"Unilateral Retinoblastoma","enrollment":84},{"nctId":"NCT03257267","phase":"PHASE3","title":"Study of Cemiplimab in Adults With Cervical Cancer","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-09-05","conditions":"Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer","enrollment":608},{"nctId":"NCT05800587","phase":"PHASE2","title":"Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2023-02-22","conditions":"Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer","enrollment":280},{"nctId":"NCT06828354","phase":"PHASE3","title":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-03-13","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT00638898","phase":"PHASE1","title":"Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2007-02-26","conditions":"Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma","enrollment":25},{"nctId":"NCT04421547","phase":"PHASE3","title":"Efficacy of Letrozole in Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-06-22","conditions":"Epithelial Ovarian Cancer","enrollment":86},{"nctId":"NCT04514497","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-20","conditions":"Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma","enrollment":28},{"nctId":"NCT03632798","phase":"PHASE3","title":"Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Cordgenics, LLC","startDate":"2018-08-01","conditions":"Recurrent Ovarian Cancer","enrollment":""},{"nctId":"NCT06612151","phase":"PHASE3","title":"A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2024-12-17","conditions":"Small Cell Lung Cancer","enrollment":438},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":20},{"nctId":"NCT03709680","phase":"PHASE2","title":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-05-24","conditions":"Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor","enrollment":128},{"nctId":"NCT06751485","phase":"PHASE3","title":"JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-01-15","conditions":"Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers","enrollment":430},{"nctId":"NCT04029688","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-01-27","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma","enrollment":38},{"nctId":"NCT06616532","phase":"PHASE3","title":"PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Biotheus Inc.","startDate":"2024-11-13","conditions":"SCLC","enrollment":404},{"nctId":"NCT02312245","phase":"PHASE2","title":"Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-07-21","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":13},{"nctId":"NCT06692166","phase":"PHASE3","title":"A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2024-09-10","conditions":"Cervical Cancer","enrollment":420},{"nctId":"NCT06669013","phase":"PHASE3","title":"Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2021-05-20","conditions":"Bone Sarcoma, Embryonal Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma","enrollment":40},{"nctId":"NCT06498479","phase":"PHASE3","title":"ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-07-04","conditions":"Small Cell Lung Cancer","enrollment":460},{"nctId":"NCT01904253","phase":"PHASE2","title":"A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2013-07","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":18},{"nctId":"NCT06581380","phase":"PHASE3","title":"JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"JenKem Technology Co., Ltd.","startDate":"2024-09-16","conditions":"Small Cell Lung Cancer","enrollment":394},{"nctId":"NCT03949283","phase":"PHASE3","title":"Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cordgenics, LLC","startDate":"2019-07-26","conditions":"Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer","enrollment":150},{"nctId":"NCT06394492","phase":"PHASE3","title":"SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-05-10","conditions":"Ovarian Cancer","enrollment":440},{"nctId":"NCT00881166","phase":"PHASE1","title":"Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2007-11","conditions":"Malignant Disease","enrollment":101},{"nctId":"NCT01798004","phase":"PHASE1","title":"Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-04-09","conditions":"Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma","enrollment":150},{"nctId":"NCT04902885","phase":"PHASE3","title":"Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-05-25","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":95},{"nctId":"NCT02200757","phase":"PHASE2","title":"Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer","status":"COMPLETED","sponsor":"ImmunityBio, Inc.","startDate":"2015-04-20","conditions":"Metastatic Small Cell Lung Cancer","enrollment":135},{"nctId":"NCT01783535","phase":"PHASE2","title":"Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-19","conditions":"Retinoblastoma","enrollment":174},{"nctId":"NCT01606878","phase":"PHASE1","title":"Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-04-29","conditions":"Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma","enrollment":46},{"nctId":"NCT06088030","phase":"PHASE2","title":"Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer","status":"RECRUITING","sponsor":"Yang Li","startDate":"2023-12-13","conditions":"Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations","enrollment":50},{"nctId":"NCT00657878","phase":"PHASE3","title":"Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2008-11","conditions":"Ovarian Cancer","enrollment":215},{"nctId":"NCT02584478","phase":"PHASE3","title":"Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)","status":"UNKNOWN","sponsor":"Advenchen Laboratories, LLC","startDate":"2015-12","conditions":"Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma","enrollment":294},{"nctId":"NCT01849874","phase":"PHASE3","title":"A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-06-27","conditions":"Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer","enrollment":341},{"nctId":"NCT05071703","phase":"PHASE4","title":"Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-08-11","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":30},{"nctId":"NCT05295589","phase":"PHASE2","title":"Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-30","conditions":"Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma","enrollment":""},{"nctId":"NCT02481830","phase":"PHASE3","title":"Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-09-14","conditions":"Lung Cancer","enrollment":569},{"nctId":"NCT02665065","phase":"PHASE3","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2016-06","conditions":"Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute","enrollment":153},{"nctId":"NCT00057837","phase":"PHASE2","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-07-14","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":140},{"nctId":"NCT03236857","phase":"PHASE1","title":"A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-11-08","conditions":"Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)","enrollment":143}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Topotecan (Chemotherapy)","genericName":"Topotecan (Chemotherapy)","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topotecan is a topoisomerase I inhibitor that works by interfering with the enzyme topoisomerase I, which is involved in DNA replication and repair. Used for Metastatic ovarian cancer, Small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}